Read a funny Instagram comment about the leveraged Korean retail investors: it’s just like wallstreetbets, but with better skin care.
It’s funny for us but not funny for them wife’s friend’s Taiwanese son is a student and owes 100s k twd now to broker/bank , it might have recovered now a bit but I feel bad for them .
[!quote] @TaiwanPlusNews
The AI boom has sent Taiwan’s stock market soaring, drawing in young investors eager to build wealth faster. Some are borrowing money to invest, taking on debt in the hope of bigger returns. But when markets turn, that strategy can lead to bigger losses. Reporter Lily LaMattina speaks to young investors about why they wanted to buy in, and the price some had to pay.
A trend as old as stock/finance markets in this world. Tulip Mania, South Sea Bubble. The list is long and broad.
So, as I’ve mentioned , I have a few investment related projects I started months ago on Claude that are grinding away.
Moog just hit an all time high. It’s in the “let’s look around the corner and ID some crucial bottlenecks in the space industry.”
This is why. The future looks good. Imma let Moog run.
Anyone owning TLN? Just bought some.
Bought it and it promptly drops 10% or so, wth?
But long-term increased energy needs should push it higher, I reckon.
Thought about buying Merck a while ago, but had not much success with pharmaceuticals in the past. So did not buy. Skin cancer treatment is a huge market.
Some people claim mrna vaccines cause turbo cancers, but now they heal cancer 
/s
Before Moderna was evil, now it’s the saviour. Is that the new thing ? Will be interesting what the anti vaxxers attitude to this will be, I know they have been working on these cancer vaccines for a longggg time.
Any claims of ‘AI was instrumental’ needs to be taken with a large dose of salt in the clinical field until now . 99% of these breakthroughs are from steady clinical research over a period of decades.
AI selected the neoantigens.
It analyzed each patient’s tumor and normal DNA/RNA sequencing data plus HLA type, then used machine-learning models to rank and pick the up to 34 mutations most likely to trigger strong T-cell responses. Separate AI handled scheduling so thousands of unique batches could be made and delivered on time.
This is groundbreaking because it is the first time a fully personalized mRNA cancer therapy has succeeded in a large Phase 3 trial—proving that a medicine designed from one individual’s tumor mutations can meaningfully outperform standard care (Keytruda alone) at preventing melanoma recurrence. The concept had been aspirational for decades; AI made the design and manufacturing practical at clinical scale.
Machine learning has been used for years and year ,if we want to call it AI , well…that’s being a bit cheeky. To get to Phase 3 would have taken enormous amounts of scientific work and money already and some positive results in the animal models.
I’m not saying AI won’t help, it definitely will, but it’s not at the base of these discoveries and therapies coming to the market. Maybe future ones like 5 or 10 years out…let’s see.
The thing about predicting is that that’s all AI can do, predict, with a personalised therapy you literally have to try it first to see if it works. One could imagine preparing a number of different vaccines for the same person could also be worth it. Hence making these quickly and affordably could be key.
The combination therapy here is pretty exciting , combination therapies seem to work the best. Very expensive I imagine.
Drug companies don’t wait around anymore to give full details , they like those stock gains
Early results show this new jab extended the length of time these patients were cancer free, but it’s unclear for how long, according to an announcement by the two firms.
Nuclear firm Newcleo to list on Nasdaq in a deal valuing it at $2.4 billion | Reuters
This is a SPAC I bought via warrants a few
Months back. I’m down 45% but I expect a buzz as we get closer to the shareholder vote.
It’s a pretty cool idea, the US has to get rid of its Cold War nuclear material and Newcleo recycles just that. They work alongside OKLO— and I find that a killer combination.
Imma double down . 
Ok.
TAIWAN REGULATOR TO ALLOW BROKERAGES TO PROVIDE US-DOLLAR MARGIN FINANCING FOR OVERSEAS STOCK AND ETF TRADING.
TAIEX RISES 0.9% TO 45,169.46 AS TAIWAN JULY INDUSTRIAL OUTPUT JUMPS 25.6% YOY, BEATING 20.7% FORECAST.
What could go wrong? 
Whoops
It hasn’t actually. It just involved a quicker analysis of the epitopes to be chosen, but as I said we use machine learning and predictive algorithms to do this work for 20 years already. These breakthroughs are iterative processes dependent on layering on decades of research to understand disease and then careful clinical trial design and huge risky investments. For instance sequencing of the human genome and tumours and HLA genes, constructing the sequences into an mRNA molecule , encapsulating it in a lipid nanoparticle, none of that is dependent on AI.
This is a positive result of a very very expensive and labour intensive clinical trial. It’s a clinical trial result not a publicly available treatment. We don’t know the cost or turn around time of this treatment.
Actually running this as a medical treatment that is standardised and affordable for patients is the next major step, this doesn’t require AI to do this, but improvements from areas such as regulatory, production, quality control, centralisation, logistics, training licensing. Getting it approved by insurance companies and governments , very little of this is dependent on AI.
Isn’t that what “practical”means here?
AI made the design and manufacturing practical at clinical scale.
And to return to this, who is claiming this?